The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CHEK | +112.12% | -76.41% | -25.08% | -100% |
| S&P | +12.66% | +85.37% | +13.13% | +228% |
Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule system for colorectal cancer screening. Its patented technology, C-Scan, is a patient-friendly preparation-free test designed to detect polyps before they may transform into cancer. The company was founded by Yoav Kimchy in 2005 and is headquartered in Isfiya, Israel.
No news articles found for Check-Cap.
| Q4 2023 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.02M | 0.0% |
| Market Cap | $12.17M | 0.0% |
| Net Income | -$3.66M | 0.0% |
| EBITDA | -$4.06M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2023 | YOY Change | |
|---|---|---|
| Net Cash | $24.76M | 0.0% |
| Inventory | 0 | 0.0% |
| Q4 2023 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Current | YOY Change | |
|---|---|---|
| Return On Invested Capital | -91.76% | 0.0% |
| Q4 2023 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.37M | 0.0% |
| Operating Free Cash Flow | -$3.37M | 0.0% |
| Metric | Q4 2023 | YoY Change |
|---|---|---|
| Price to Book | 0.44 | - |
| Price to Tangible Book Value | 0.44 | - |
| Enterprise Value to EBITDA | 3.10 | - |
| Total Debt | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
